Hiligsmann M, Evers SM, Ben Sedrine W et al (2015) A systematic review of cost-effectiveness analyses of drugs for postmenopausal osteoporosis. Pharmacoeconomics 33(3):205–224. 10.1007/s40273-014-0231-1 DOI: 10.1007/s40273-014-0231-1
Li N, Cornelissen D, Silverman S et al (2021) An updated systematic review of cost-effectiveness analyses of drugs for osteoporosis. Pharmacoeconomics 39(2):181–209. 10.1007/s40273-020-00965-9 DOI: 10.1007/s40273-020-00965-9
Wu CH, Kao IJ, Hung WC et al (2018) Economic impact and cost-effectiveness of fracture liaison services: a systematic review of the literature. Osteoporos Int 29(6):1227–1242. 10.1007/s00198-018-4411-2 DOI: 10.1007/s00198-018-4411-2
Nayak S, Roberts MS, Greenspan SL (2011) Cost-effectiveness of different screening strategies for osteoporosis in postmenopausal women. Ann Intern Med 155(11):751–761. 10.7326/0003-4819-155-11-201112060-00007 DOI: 10.7326/0003-4819-155-11-201112060-00007
Turner DA, Khioe RFS, Shepstone L et al (2018) The cost-effectiveness of screening in the community to reduce osteoporotic fractures in older women in the UK: economic evaluation of the SCOOP Study. J Bone Miner Res 33(5):845–851. 10.1002/jbmr.3381 DOI: 10.1002/jbmr.3381
Kanis JA, Harvey N, Cooper C, et al. (2016) A systematic review of intervention thresholds based on FRAX: a report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation. Arch Osteoporos 11(1). 10.1007/s11657-016-0278-z
Husereau D, Drummond M, Petrou S et al (2013) Consolidated health economic evaluation reporting standards (CHEERS) statement. Value Heal 16(2):e1. 10.1016/j.jval.2013.02.010 DOI: 10.1016/j.jval.2013.02.010
Hiligsmann M, Reginster J, Tosteson ANA et al (2019) Recommendations for the conduct of economic evaluations in osteoporosis: outcomes of an experts ’ consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Osteoporos Int 30(1):45–57. 10.1007/s00198-018-4744-x DOI: 10.1007/s00198-018-4744-x
Cui L, He T, Jiang Y et al (2020) Predicting the intervention threshold for initiating osteoporosis treatment among postmenopausal women in China: a cost-effectiveness analysis based on real-world data. Osteoporos Int 31(2):307–316. 10.1007/s00198-019-05173-6 DOI: 10.1007/s00198-019-05173-6
Mori T, Crandall CJ, Fujii T, Ganz DA (2021) Cost-effectiveness of zoledronic acid compared with sequential denosumab/alendronate for older osteoporotic women in Japan. Arch Osteoporos 16(1). https://doi.org/10.1007/s11657-021-00956-z
Hiligsmann M, Williams SA, Fitzpatrick LA, Silverman SS, Weiss R, Reginster JY (2019) Cost-effectiveness of sequential treatment with abaloparatide vs. teriparatide for United States women at increased risk of fracture. Semin Arthritis Rheum 49(2):184–196. 10.1016/j.semarthrit.2019.01.006
Hiligsmann M, Maggi S, Veronese N, Sartori L, Reginster JY (2021) Cost-effectiveness of buffered soluble alendronate 70 mg effervescent tablet for the treatment of postmenopausal women with osteoporosis in Italy. Osteoporos Int 32(3):595–606. 10.1007/s00198-020-05802-5 DOI: 10.1007/s00198-020-05802-5
Ito K (2020) Cost-effectiveness of screening for osteoporosis in older men with a history of falls. JAMA Netw open 3(12):e2027584. 10.1001/jamanetworkopen.2020.27584 DOI: 10.1001/jamanetworkopen.2020.27584
Hiligsmann M, Williams SA, Fitzpatrick LA, Silverman SS, Weiss R, Reginster JY (2020) Cost-effectiveness of sequential treatment with abaloparatide followed by alendronate vs. alendronate monotherapy in women at increased risk of fracture: a US payer perspective. Semin Arthritis Rheum 50(3):394–400. 10.1016/j.semarthrit.2020.02.004
Husereau D, Drummond M, Augustovski F et al (2022) CHEERS 2022 ISPOR Good Research Practices Task Force Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. Value Health 25(1):3–9 DOI: 10.1016/j.jval.2021.11.1351
